Screening for ovarian cancer in women with varying levels of risk, using annual tests, results in high recall for repeat screening tests

• Published in: Hereditary cancer in clinical practice 2011-11, Vol.9 (1), p.11-11, Article 11
• Main Authors: Nobbenhuis, Marielle Ae, Bancroft, Elizabeth, Moskovic, Eleanor, Lennard, Fiona, Pharoah, Paul, Jacobs, Ian, Ward, Ann, Barton, Desmond Pj, Ind, Thomas Ej, Shepherd, John H, Bridges, Jane E, Gore, Martin, Haracopos, Chris, Shanley, Susan, Ardern-Jones, Audrey, Thomas, Sarah, Eeles, Ros
• Format: Article
• Language: English
• Subjects: Age; bilateral salpingo-oophorectomy; BRCA gene mutation; Breast cancer; Cancer; Diagnosis; Females; Gene mutations; Genetic aspects; Genetic screening; Genetics; Health aspects; Hospitals; Medical research; Mutation; Ovarian cancer; Ovarian carcinoma; Risk assessment; screening; serum CA125; transvaginal ultrasound; Women; Womens health
• ISSN: 1897-4287; 1731-2302; 1897-4287
• DOI: 10.1186/1897-4287-9-11

We assessed ovarian cancer screening outcomes in women with a positive family history of ovarian cancer divided into a low-, moderate- or high-risk group for development of ovarian cancer. 545 women with a positive family history of ovarian cancer referred to the Ovarian Screening Service at the Royal Marsden Hospital, London from January 2000- December 2008 were included. They were stratified into three risk-groups according to family history (high-, moderate- and low-risk) of developing ovarian cancer and offered annual serum CA 125 and transvaginal ultrasound screening. The high-risk group was offered genetic testing. The median age at entry was 44 years. The number of women in the high, moderate and low-risk groups was 397, 112, and 36, respectively. During 2266 women years of follow-up two ovarian cancer cases were found: one advanced stage at her fourth annual screening, and one early stage at prophylactic bilateral salpingo-oophorectomy (BSO). Prophylactic BSO was performed in 138 women (25.3%). Forty-three women had an abnormal CA125, resulting in 59 repeat tests. The re-call rate in the high, moderate and low-risk group was 14%, 3% and 6%. Equivocal transvaginal ultrasound results required 108 recalls in 71 women. The re-call rate in the high, moderate, and low-risk group was 25%, 6% and 17%. No early stage ovarian cancer was picked up at annual screening and a significant number of re-calls for repeat screening tests was identified.